COSTI, Maria Paola
 Distribuzione geografica
Continente #
NA - Nord America 28.303
EU - Europa 17.952
AS - Asia 8.206
SA - Sud America 1.060
AF - Africa 97
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 26
Totale 55.676
Nazione #
US - Stati Uniti d'America 28.105
GB - Regno Unito 5.288
IT - Italia 4.419
SG - Singapore 2.691
CN - Cina 2.495
DE - Germania 2.379
SE - Svezia 1.758
HK - Hong Kong 1.575
BR - Brasile 934
RU - Federazione Russa 819
FR - Francia 702
UA - Ucraina 618
FI - Finlandia 490
TR - Turchia 379
PL - Polonia 299
BG - Bulgaria 268
KR - Corea 232
ID - Indonesia 187
IN - India 170
CA - Canada 160
BE - Belgio 158
NL - Olanda 134
IE - Irlanda 130
VN - Vietnam 101
LT - Lituania 84
CH - Svizzera 82
ES - Italia 71
JP - Giappone 67
IR - Iran 54
AT - Austria 47
AR - Argentina 43
CZ - Repubblica Ceca 43
ZA - Sudafrica 43
MY - Malesia 41
BD - Bangladesh 32
EC - Ecuador 26
PT - Portogallo 26
RO - Romania 24
PK - Pakistan 23
AU - Australia 22
CL - Cile 21
EU - Europa 21
MX - Messico 20
LU - Lussemburgo 17
DK - Danimarca 15
EG - Egitto 15
IQ - Iraq 15
TW - Taiwan 15
MA - Marocco 14
UZ - Uzbekistan 14
GR - Grecia 12
KZ - Kazakistan 12
AE - Emirati Arabi Uniti 11
HU - Ungheria 11
JO - Giordania 11
PH - Filippine 11
AZ - Azerbaigian 10
NZ - Nuova Zelanda 10
NO - Norvegia 9
CO - Colombia 8
KE - Kenya 8
SA - Arabia Saudita 8
VE - Venezuela 8
IL - Israele 7
MD - Moldavia 7
NP - Nepal 7
PE - Perù 7
AL - Albania 6
BY - Bielorussia 6
JM - Giamaica 6
KG - Kirghizistan 6
LI - Liechtenstein 6
RS - Serbia 6
TH - Thailandia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
BO - Bolivia 5
GE - Georgia 5
OM - Oman 5
PY - Paraguay 5
SK - Slovacchia (Repubblica Slovacca) 5
TN - Tunisia 5
AM - Armenia 4
DZ - Algeria 4
TZ - Tanzania 4
BA - Bosnia-Erzegovina 3
DO - Repubblica Dominicana 3
EE - Estonia 3
HN - Honduras 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
UY - Uruguay 3
BH - Bahrain 2
CY - Cipro 2
GT - Guatemala 2
LK - Sri Lanka 2
MO - Macao, regione amministrativa speciale della Cina 2
SI - Slovenia 2
BZ - Belize 1
CR - Costa Rica 1
ET - Etiopia 1
Totale 55.668
Città #
Southend 3.800
Santa Clara 3.341
Fairfield 2.982
Houston 2.332
Woodbridge 2.114
Chandler 2.090
Ashburn 1.947
Singapore 1.570
Hong Kong 1.556
Ann Arbor 1.257
Jacksonville 1.238
Frankfurt am Main 1.193
Seattle 1.149
Dearborn 1.142
Cambridge 1.113
Wilmington 1.049
Nyköping 1.012
Modena 798
London 745
Hefei 537
Beijing 432
New York 354
Princeton 289
San Diego 271
Sofia 266
Kraków 255
Moscow 252
Shanghai 238
Helsinki 232
Eugene 229
Seoul 200
Milan 199
Izmir 195
Jakarta 178
Fremont 175
Bologna 163
Redwood City 154
Boardman 151
Brussels 128
Council Bluffs 128
Des Moines 126
Bremen 123
Dublin 120
Munich 107
Rome 103
Los Angeles 92
Ottawa 87
Parma 87
Reggio Emilia 74
Falls Church 67
The Dalles 65
Guangzhou 63
São Paulo 62
Grafing 58
Turku 57
Dong Ket 52
Verona 50
Naples 47
Turin 46
Norwalk 45
San Mateo 45
Milwaukee 42
Nanjing 42
Padova 41
Jinan 38
Phoenix 38
Amsterdam 36
Nuremberg 36
Kunming 34
Toronto 34
Paris 33
Ferrara 32
Washington 32
Brooklyn 31
Chicago 31
Belo Horizonte 30
Brno 30
Perugia 30
Formigine 29
Napoli 29
Warsaw 28
Ho Chi Minh City 27
Rio de Janeiro 25
Vienna 25
Sassuolo 24
Wuhan 24
Zurich 24
Brasília 23
Hangzhou 23
Piacenza 23
Saint Petersburg 23
San Francisco 22
Auburn Hills 21
Dallas 21
Lauterbourg 21
Portsmouth 21
Prato 21
Florence 19
Kilburn 19
Lappeenranta 19
Totale 40.131
Nome #
Structure-based discovery and in-parallel optimization of novel competitive inhibitors of thymidylate synthase 1.114
STRUTTURA DEL CRISTALLO DEL COMPLESSO DI TIMIDILATO SINTETASI (TS) CON UN LIGANDO 723
TYDOCK PHARMA s.r.l. Spin Off dell'Università di Modena e Reggio Emilia che ha come fine l'attività di ricerca e sviluppo nel settore delle biotech farmaceutiche. 502
Metodo per la funzionalizzazione sito specifica di molecole proteiche 372
Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics 361
Virtual Screening and X-ray Crystallography Identify Non-Substrate Analog Inhibitors of Flavin-Dependent Thymidylate Synthase 360
An Improved Synthesis of CENTA, a Chromogenic Substrate for β-Lactamases 344
USO DI INIBITORI DELLA PTERIDINA REDUTTASI PER LA PREVENZIONE E/O IL TRATTAMENTO DI INFEZIONI PARASSITARIE 335
Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase 335
Internalization and stability of a thymidylate synthase peptide inhibitor in ovarian cancer cells 332
Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase 325
Aryl thiosemicarbazones for the treatment of trypanosomatidic infections 314
Optimization of Peptides That Target Human Thymidylate Synthase to Inhibit Ovarian Cancer Cell Growth 306
Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology 302
Conveying a newly designed hydrophilic anti-human thymidylate synthase peptide to cisplatin resistant cancer cells: are pH-sensitive liposomes more effective than conventional ones? 300
Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform 299
Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides 297
Enhanced anti-hyperproliferative activity of human thymidylate synthase inhibitor peptide by solid lipid nanoparticle delivery 295
Repurposing of drugs targeting yap-tead functions 295
Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance 294
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 292
Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines. 287
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs 284
Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth 281
Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth 278
Translational repression of thymidylate synthase by targeting its mRNA 276
2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes 273
The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment 272
NUOVE MOLECOLE, PER USO COME AGENTI ANTITUMORALI 271
Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells. 271
Antibacterial agent discovery using thymidylate synthase biolibrary screening 270
Current and Future Chemotherapy for Chagas Disease 270
Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections 269
Decoding the structural basis for carbapenem hydrolysis by class A β- lactamases: fishing for a pharmacophore 263
Crystal Structure of histidine-tagged human thymidylate synthase 259
pH-Promoted Release of a Novel Anti-Tumour Peptide by “Stealth” Liposomes: Effect of Nanocarriers on the Drug Activity in Cis-Platinum Resistant Cancer Cells 259
Constrained dansyl derivatives reveal bacterial specificity of highly conserved Thymidylate Synthases A 258
2′-Deoxyuridine 5′-Monophosphate Substrate Displacement in Thymidylate Synthase through 6-Hydroxy-2H-naphtho[1,8-bc]furan-2-one Derivatives 256
Spermidine/spermine N1-acetyltranferasemodulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistanthuman ovarian cancer cell lines 254
Alanine Mutants of the Interface Residues of Human Thymidylate Synthase Decode Key Features of the Binding Mode of Allosteric Anticancer Peptides 253
Excited-state intramolecular proton transfer in a bioactive flavonoid provides fluorescence observables for recognizing its engagement with target proteins 252
ACS Medicinal Chemistry Letters. member of the Editorial Board 251
Proteomic Approach to the Detection of the Mechanism of Action of Anticancer Peptides 251
Structure-Based Selectivity Optimization of Piperidine–Pteridine Derivatives as Potent Leishmania Pteridine Reductase Inhibitors 249
Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-beta-lactamases 249
Multiligand approach to the identification of resistant strains overexpressing beta-lactamase 248
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells 247
Permeation through the cell membrane of a boron-based β-lactamase inhibitor. 246
Crystal Structure of human thymidylate synthase bound to a peptide inhibitor 246
Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity 246
Structure-based studies on species-specific inhibition of thymidylate synthase 245
Thymidylate synthase inhibition: A structure-based rationale for drug design 245
Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To InhibitTrypanosoma bruceiPteridine Reductase in Support of Early-Stage Drug Discovery 244
Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds 243
Development of a Focused Library of Triazole-Linked Privileged-Structure-Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections 243
Hotspots in an obligate homodimeric anticancer target. structural and functional effects of interfacial mutations in human thymidylate synthase 243
Proteomic and bioinformatic studies for the characterization of response to pemetrexed in platinum drug resistant ovarian cancer 243
“A step further in the discovery of phthalein derivatives as Thymidylate Synthase inhibitors” 242
X-ray-crystallography deciphers the activity of broad spectrum boronic acid β-Lactamases inhibitors 242
Dimer-monomer equilibrium of human thymidylate synthase monitored by fluorescence resonance energy transfer 241
Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells 240
Ligand-based discovery of N-(1,3-dioxo-1H,3H-benzo[de]isochromen-5-yl)-carboxamide and sulfonamide derivatives as thymidylate synthase A inhibitors 236
PTEROATE-PEPTIDE BIOCONJUGATE TARGETING THE FOLATE RECEPTOR IN HUMAN OVARIAN CANCER CELL LINES: TRANSPORT AND MECHANISM OF ACTION. 236
Design and characterization of a mutation outside the active site of human thymidylate synthase that affects ligand binding 235
Conformational analysis of phthalein derivatives acting as thymidylate synthase inhibitors by means of 1H NMR and quantum chemical calculations 234
Thymidylate synthase structure, function and implication in drug discovery 234
IN SILICO/IN VITRO APPROACHES FOR THE IDENTIFICATION OF NEW CARBAPENEMASE INHIBITORS 234
Maxwell A: F1000Prime Recommendation of Evaluation [Neres J et al., ACS Chem Biol 2014]. In F1000Prime, 09 Jan 2015; DOI: 10.3410/f.725248139.793502885. F1000Prime.com/725248139#eval793502885 234
A condensed thiadiazolo-pyrimidine as a new efficient fluorophore. Theoretical and experimental investigation of the electronic spectra and photophysics 232
Comparative mapping of on-targets and off-targets for the discovery of anti-trypanosomatid folate pathway inhibitors 232
A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells 232
Allosteric Inhibition of human Thymidylate Synthase. 232
Theoretical study of electronic spectra and photophysics of uracil derivatives. 231
Aprepitant as anticancer drug 228
SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent 228
Theoretical analysis of the addition of hydroxylamine to uracil and 5-fluorouracil as a model for the Thymidylate synthase reaction 226
Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus 226
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 226
MITO-group Multicenter italian trials in ovarian cancer and gynecological malignancies Borad of directors-translational research group 226
ANTICANCER DRUGS 225
Tethering low affinity ligands to the dimeric interface of human thymidylate synthase. 223
Homodimeric Enzymes as Drug Targets 222
Optimization of N-alkylation in the Synthesis of Methotrexate and Pteridine-based Derivatives Under Microwave-Irradiation 221
A proteomic approach to investigate the mechanism of action of anticancer peptides 219
Zing meeting on Medicinal Chemistry 2012-Lanzarote-invitated lecture 219
The 1,10-phenanthroline ligand enhances the antiproliferative activity of dna-intercalating thiourea-pd(Ii) and-pt(ii) complexes against cisplatin-sensitive and-resistant human ovarian cancer cell lines 218
CYCLIZATION REACTIONS OF 1,3-DIBROMOPROPAN-2-OL, 2,3-DIBROMOPROPAN-1-OL AND 1-BROMOMETHYLOXIRANE WITH 6-AMINO-2,3-DIHYDRO-2-THIOXO-4(1H)-PYRIMIDINONE 217
Biochemical effects of riluzole on Leishmania parasites 217
Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity 217
Protein-protein interaction inhibitors: case studies on Small Molecules and Natural Compounds. 215
Update on antifolate drugs targets 215
Development of flavonoids derivatives as leads against Leishmaniasis and Trypanosomiasis-invited lecture 215
Optimizing Cell Permeation of an Antibiotic Resistance Inhibitor for Improved Efficacy 215
Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case 213
Alternative strategies in medicinal chemistry to face drug resistance in anticancer therapy. 212
Inhibitor of Ovarian Cancer Cells growth by Virtual Screening: A New Thiazole Derivative Targeting Human Thymidylate Synthase 210
Chairperson EUTROC- Mayo Conference-Berlin - Preliminary characterization of pharmacodynamic biomarkers for LR-peptide growth inhibition of ovarian cancer (OC) cell models. 210
Design, synthesis and biological evaluation of non-covalent AmpC Beta-Lactamases inhibitors 210
New thymidylate synthase inhibitors induce apoptosis in melanoma cell lines 209
Ligand-Based Virtual Screening and ADME-Tox Guided Approach to Identify Triazolo-quinoxalines as Folate Cycle Inhibitors. 209
Totale 27.050
Categoria #
all - tutte 219.062
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 219.062


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020469 0 0 0 0 0 0 0 0 0 0 0 469
2020/20217.774 750 311 736 642 848 621 558 770 381 1.171 571 415
2021/20225.532 246 536 330 303 243 554 249 356 626 393 1.058 638
2022/20236.329 759 759 421 608 644 897 190 604 753 103 308 283
2023/20245.689 202 278 326 412 1.996 486 280 492 138 133 387 559
2024/202514.039 602 197 432 947 2.670 1.880 988 807 1.437 649 1.712 1.718
Totale 56.389